A spinal cord injury patient in Houston received a peripheral nerve stimulator last week, but the surgery did not look like one. There was no incision and no spinal cord stimulator pulse generator buried in the back. A clinician used a single 18-gauge needle under local anaesthesia to deliver a thin helical platinum-iridium electrode to a peripheral nerve, then connected it to an external pulse generator the patient wears. Neuronoff, the Cleveland startup behind the device, announced on 5 June 2026 that this is the first patient implanted in a US Department of Defense-funded clinical trial of its Injectrode platform for neurogenic bladder dysfunction after spinal cord injury. The trial is registered as NCT07264868 and is being run at UT Health Houston under principal investigator Dr Argyrios Stampas, Professor of Physical Medicine and Rehabilitation at McGovern Medical School.

What the Injectrode is and how it sits in the bioelectronic-medicine cohort

The Injectrode is a tripolar electrode with a helical platinum-iridium architecture, roughly 1.5 millimetres wide, delivered through an 18-gauge needle without the one- to two-inch incision that conventional spinal cord stimulator placement still requires. Inside BCI covered the broader Injectrode platform on 5 April 2026 when Neuronoff disclosed a three-month chronic large animal study showing the device could pair with off-the-shelf implantable pulse generators through standard Bal Seal connectors. The April story was the architectural case for the platform. Today’s announcement is the first commercially material clinical milestone in spinal cord injury, the patient population that anchors the Department of Defense’s neurogenic bladder programme funding rationale.

Neurogenic bladder is one of the most frequent and clinically demanding secondary complications of spinal cord injury. Loss of voluntary bladder control affects the majority of SCI patients to some degree and is independently associated with reduced quality of life, repeated urinary tract infections, and downstream kidney disease. The standard non-surgical therapies are pharmacological (anticholinergics, beta-3 agonists) and procedural (clean intermittent catheterisation, botulinum toxin injection of the bladder wall). Implantable neuromodulation therapies (sacral neuromodulation devices like Medtronic InterStim) have historically required general anaesthesia and a surgical pocket implantation that limits their accessibility for SCI patients with autonomic dysreflexia risk.

The Injectrode’s claim to differentiation is procedural simplicity: a peripheral nerve electrode placed under local anaesthesia through a single needle, with an external pulse generator that avoids both surgical pocket implantation and battery-replacement procedures. If the trial shows efficacy, it sits in the same clinical space as Medtronic InterStim and the implantable tibial neuromodulation devices (BlueWind Revi, Medtronic Altaviva) but at a structurally lower procedural-complexity tier.

Trial design

The trial is a Phase 1/2 randomised double-blind controlled study enrolling 21 participants across three arms: unilateral active stimulation, bilateral active stimulation, and sham stimulation. Primary endpoints at 4 and 8 weeks assess device performance (safety, stimulation accuracy and reliability, procedural feasibility, physician and patient acceptability). Secondary endpoints evaluate bladder function and changes in overactive bladder medication use. As the first-in-SCI human study of the Injectrode platform, the trial is designed to generate the safety and feasibility data that will support an FDA presubmission and inform the design of a subsequent pivotal trial.

The principal investigator, Dr Argyrios Stampas, is a board-certified Physical Medicine and Rehabilitation physician at UT Health Houston with an active research programme in spinal cord injury neurogenic bowel and bladder dysfunction. Neuronoff has previously received $5 million in combined US Department of Defense and National Institutes of Health funding (announced January 2025) to advance the Injectrode through clinical development. The current trial is the first DoD-funded clinical study in that programme to enrol and implant a patient.

The bioelectronic-medicine inflection backdrop

The Injectrode trial sits inside a broader bioelectronic-medicine commercial inflection that has hardened across the past six months. Inside BCI has covered CVRx’s Barostim moving from Category III to Category I CPT codes on 1 January 2026 and the first Humana Medicare Advantage coverage policy on 14 May 2026. Boston Scientific completed its acquisition of Nalu Medical for approximately $533 million on 27 January 2026. Medtronic announced its acquisition of SPR Therapeutics for approximately $650 million on 20 May 2026. BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026. The Neuronoff first-in-SCI implant is the next clinical milestone in the same category.

The DoD funding is structurally relevant. The Department of Defense’s Spinal Cord Injury Research Program (SCIRP) and Congressionally Directed Medical Research Programs (CDMRP) have been a consistent funder of US neuromodulation clinical work over the past decade, with VA-anchored clinical sites and military service member patient populations as the dual rationale. A DoD-funded trial that reaches first-in-human implantation status is structurally further along than an equivalent NIH-funded preclinical programme, even when the dollar amounts look similar.

What to watch

The first signal is the 4-week and 8-week primary endpoint readout. The trial’s stated primary endpoints are device-performance metrics rather than bladder-function efficacy, which means the first readout will not yet establish whether the Injectrode produces measurable clinical benefit in SCI patients. A clean device-performance readout still moves the company toward an FDA presubmission and a subsequent pivotal trial. The second signal is the rate of new patient enrolment toward the 21-participant target. The first implant is the 5 June 2026 milestone; the pace of cohort completion will determine whether the 4-week and 8-week readouts arrive at the back half of 2026 or stretch into 2027. The third signal is whether other clinical sites join the trial beyond UT Health Houston. A single-site trial enrolment trajectory is materially different from a multi-site DoD-funded clinical network, particularly for a 21-participant cohort that could complete enrolment faster across multiple sites.

Sources

• Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode for Neurogenic Bladder in Spinal Cord Injury (PR Newswire, 5 June 2026)
• Clinical Trial NCT07264868 (ClinicalTrials.gov)
• 1st patient implanted in spinal cord injury neuromodulation trial (Becker’s Spine Review, 5 June 2026)
• Neuronoff Secures $5 Million in DOD and NIH Funding to Advance Minimally Invasive Neuromodulation Platform (PR Newswire / Yahoo Finance, January 2025)
• Neuronoff corporate site